Pfizer to discontinue its GLP-1 pill for obesity due to liver toxicity (STAT)

Pfizer has discontinued its experimental oral GLP-1 drug, danuglipron, for obesity treatment after a clinical trial volunteer showed signs of potential drug-induced liver injury, which later resolved. Despite the setback, Pfizer affirmed its continued commitment to obesity research through other drug candidates. The move ends a turbulent journey for the program, which once drew investor optimism amid the rising popularity of GLP-1 therapies like Ozempic.